Vesalius Cardiovascular Announces the Completion of a Successful Chronic Animal Study

VANCOUVER, British Columbia, January 21, 2020 (Newswire.com) Vesalius Cardiovascular Inc. (VCI), a pre-clinical stage medical device company developing novel percutaneous therapies for the treatment of mitral regurgitation, today announced the successful completion of their first 30-day chronic animal study using their mitral valve repair device. The predetermined endpoints of the study were the absence of […]

Vesalius team is attending TCT 2019 in San Francisco

September 25-29, 2019 – Moscone Convention Center, San Francisco Vesalius team is attending TCT 2019 in San Francisco. This very specialized conference is the ideal occasion to learn more about the latest therapies in interventional cardiology and connect with corporations active in this field. 

Vesalius is featured in the Life Sciences Bristish Columbia (LSBC) Annual Magazine 2019

February 20, 2019 – LSBC, Vancouver As the premier marketing piece for the BC life science ecosystem, LifeSciences BC publishes an annual magazine that identifies the innovation, pace and significant accomplishments of the life sciences sector in the last year. The 2019 theme for the magazine is Transformative Medicine: Targeted Insights – Advancing Discoveries. On […]

Vesalius Successful at Cascadia Venture Forum Vancouver

October 12, 2017 – VentureLabs, Vancouver. Vesalius Cardiovascular finishes in first place at the Vancouver Cascadia Venture Forum, from a field of 6 startup ventures in the Seed category, as voted by the audience of angels, VCs, entrepreneurs, and business mentors. Vesalius will now proceed to the Cascadia Summit Competition to be held in Seattle […]